The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial introduction generated massive gains, the end of its intellectual property protection opened the floodgates to cheaper versions, dramatically eroding revenue. This poses a specific risk for drug manufacturers relying on comparable blockbuster offerings, su

The legacy of Viagra, and its creator copyright, presents a complex case study for investors. Originally a blockbuster drug, yielding billions in revenue , its patent expiration created a flood of knock-off medications, significantly eroding its market share . While specific businesses may seek to capitalize on male sexual dysfunction, the current